A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites

Toxic effects and immunologic results

G. Melioli, M. R. Sertoli, M. Bruzzone, M. T. Nobile, R. Rosso, P. L. Percivale, A. Catturich, F. Badellino, N. Balletto, D. Civalleri, A. M. Machi', A. Galatska, L. Santi, L. Moretta

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A phase I study to evaluate the use of i.p. infusion of recombinant interleukin-2 (rIL-2) was planned. The following dose levels were calculated: 0.1, 0.3, 1.0, 3.0 and 10 mg/m2/day for 14 days, but only the second levels were reached. In this trial the acute toxic effects at this dosage included cardiac ischemia, transient liver impairment and septic peritonitis. The maximum tolerated dose (MTD) was 0.3 mg/m2/day for 14 days. In addition, two patients developed peritoneal fibrosis. No objective responses were observed. Therefore, in order to explore the biological activity of low (nontoxic) doses, three patients (one untreated and two previously treated with rIL-2) were infused with 0.01 and 0.03 mg/m2/day for 7 days. Potentiation of cytolytic activities in peritoneal lymphocytes and activation of a lymphokine cascade in the ascitic fluid were observed at doses ranging from 0.03 mg/m2/day to 0.3 mg/m2/day. These findings in association with the toxic effects observed at the MTD suggest the use of the minimum effective dose for future locoregional immunotherapeutic protocols.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number3
Publication statusPublished - 1991

Fingerprint

Parenteral Infusions
Maximum Tolerated Dose
Poisons
Ascites
Interleukin-2
Peritoneal Fibrosis
Lymphokines
Ascitic Fluid
Lymphocyte Activation
Peritonitis
Ischemia
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites : Toxic effects and immunologic results. / Melioli, G.; Sertoli, M. R.; Bruzzone, M.; Nobile, M. T.; Rosso, R.; Percivale, P. L.; Catturich, A.; Badellino, F.; Balletto, N.; Civalleri, D.; Machi', A. M.; Galatska, A.; Santi, L.; Moretta, L.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 14, No. 3, 1991, p. 231-237.

Research output: Contribution to journalArticle

Melioli, G, Sertoli, MR, Bruzzone, M, Nobile, MT, Rosso, R, Percivale, PL, Catturich, A, Badellino, F, Balletto, N, Civalleri, D, Machi', AM, Galatska, A, Santi, L & Moretta, L 1991, 'A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: Toxic effects and immunologic results', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 14, no. 3, pp. 231-237.
Melioli, G. ; Sertoli, M. R. ; Bruzzone, M. ; Nobile, M. T. ; Rosso, R. ; Percivale, P. L. ; Catturich, A. ; Badellino, F. ; Balletto, N. ; Civalleri, D. ; Machi', A. M. ; Galatska, A. ; Santi, L. ; Moretta, L. / A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites : Toxic effects and immunologic results. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1991 ; Vol. 14, No. 3. pp. 231-237.
@article{e78a2f1833c24187ba2cc9721e4f0396,
title = "A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: Toxic effects and immunologic results",
abstract = "A phase I study to evaluate the use of i.p. infusion of recombinant interleukin-2 (rIL-2) was planned. The following dose levels were calculated: 0.1, 0.3, 1.0, 3.0 and 10 mg/m2/day for 14 days, but only the second levels were reached. In this trial the acute toxic effects at this dosage included cardiac ischemia, transient liver impairment and septic peritonitis. The maximum tolerated dose (MTD) was 0.3 mg/m2/day for 14 days. In addition, two patients developed peritoneal fibrosis. No objective responses were observed. Therefore, in order to explore the biological activity of low (nontoxic) doses, three patients (one untreated and two previously treated with rIL-2) were infused with 0.01 and 0.03 mg/m2/day for 7 days. Potentiation of cytolytic activities in peritoneal lymphocytes and activation of a lymphokine cascade in the ascitic fluid were observed at doses ranging from 0.03 mg/m2/day to 0.3 mg/m2/day. These findings in association with the toxic effects observed at the MTD suggest the use of the minimum effective dose for future locoregional immunotherapeutic protocols.",
author = "G. Melioli and Sertoli, {M. R.} and M. Bruzzone and Nobile, {M. T.} and R. Rosso and Percivale, {P. L.} and A. Catturich and F. Badellino and N. Balletto and D. Civalleri and Machi', {A. M.} and A. Galatska and L. Santi and L. Moretta",
year = "1991",
language = "English",
volume = "14",
pages = "231--237",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites

T2 - Toxic effects and immunologic results

AU - Melioli, G.

AU - Sertoli, M. R.

AU - Bruzzone, M.

AU - Nobile, M. T.

AU - Rosso, R.

AU - Percivale, P. L.

AU - Catturich, A.

AU - Badellino, F.

AU - Balletto, N.

AU - Civalleri, D.

AU - Machi', A. M.

AU - Galatska, A.

AU - Santi, L.

AU - Moretta, L.

PY - 1991

Y1 - 1991

N2 - A phase I study to evaluate the use of i.p. infusion of recombinant interleukin-2 (rIL-2) was planned. The following dose levels were calculated: 0.1, 0.3, 1.0, 3.0 and 10 mg/m2/day for 14 days, but only the second levels were reached. In this trial the acute toxic effects at this dosage included cardiac ischemia, transient liver impairment and septic peritonitis. The maximum tolerated dose (MTD) was 0.3 mg/m2/day for 14 days. In addition, two patients developed peritoneal fibrosis. No objective responses were observed. Therefore, in order to explore the biological activity of low (nontoxic) doses, three patients (one untreated and two previously treated with rIL-2) were infused with 0.01 and 0.03 mg/m2/day for 7 days. Potentiation of cytolytic activities in peritoneal lymphocytes and activation of a lymphokine cascade in the ascitic fluid were observed at doses ranging from 0.03 mg/m2/day to 0.3 mg/m2/day. These findings in association with the toxic effects observed at the MTD suggest the use of the minimum effective dose for future locoregional immunotherapeutic protocols.

AB - A phase I study to evaluate the use of i.p. infusion of recombinant interleukin-2 (rIL-2) was planned. The following dose levels were calculated: 0.1, 0.3, 1.0, 3.0 and 10 mg/m2/day for 14 days, but only the second levels were reached. In this trial the acute toxic effects at this dosage included cardiac ischemia, transient liver impairment and septic peritonitis. The maximum tolerated dose (MTD) was 0.3 mg/m2/day for 14 days. In addition, two patients developed peritoneal fibrosis. No objective responses were observed. Therefore, in order to explore the biological activity of low (nontoxic) doses, three patients (one untreated and two previously treated with rIL-2) were infused with 0.01 and 0.03 mg/m2/day for 7 days. Potentiation of cytolytic activities in peritoneal lymphocytes and activation of a lymphokine cascade in the ascitic fluid were observed at doses ranging from 0.03 mg/m2/day to 0.3 mg/m2/day. These findings in association with the toxic effects observed at the MTD suggest the use of the minimum effective dose for future locoregional immunotherapeutic protocols.

UR - http://www.scopus.com/inward/record.url?scp=0025773898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025773898&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 231

EP - 237

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -